Is GILD Worth Buying in 2026?

Gilead Sciences Inc

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-06-07

Here’s whether Gilead Sciences Inc (GILD) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); RSI 49 — healthy momentum range; strong 1-year return of +16.9%; rising volume confirms the move (1.26x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.39% over 10 days); 3-month momentum negative (-11.9%). Currently 17.9% off its 52-week high. Score: +2/7.

Ready to act on this? 📈 Trade on Webull

GILD is holding above its long-term 200-day MA ($128.92) but has slipped below the 50-day MA ($134.18), pointing to short-term weakness in an otherwise intact trend. An RSI of 48.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +16.9% compares to +24.4% for SPY (trailed the market by 7.4%).

$10,000 invested 1 year ago → $11,693 today
vs. S&P 500 (SPY) — same period trailed market by 7.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($128.92)
Above 50-day MA ($134.18)
RSI(14) neutral zone (30–70) — currently 48.9
Positive return (+16.9%)
!Within 10% of period high (−17.9%)
Period Range $129.16
$104.46 $157.29
RSI (14) 48.9
0 · OversoldOverbought · 100

Key Metrics

Price$129.16
Period Return+16.9%
Period High$157.29
Period Low$104.46
Drawdown−17.9%
MA-50$134.18
MA-200$128.92
RSI (14)48.9
Avg Volume (30d)7.2M
vs. SPYtrailed by 7.4%
Return Rank#561 of 1245

Trade GILD

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers